Donor T Cell Therapy for Adenovirus Infections
Trial Summary
What is the purpose of this trial?
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on certain high doses of prednisone or have recently received specific treatments like anti-thymocyte globulin or donor lymphocyte infusion.
What data supports the effectiveness of the treatment Donor T Cell Therapy for adenovirus infections?
Research shows that using virus-specific T cells (VSTs) to treat adenovirus infections in patients who have had stem cell transplants is highly effective, with 81% of patients showing improvement and 58% achieving complete recovery. This approach is particularly beneficial for those with weakened immune systems, as traditional antiviral drugs often have limited success and can cause significant side effects.12345
Is Donor T Cell Therapy for Adenovirus Infections safe for humans?
Research indicates that Donor T Cell Therapy, also known as Virus-Specific T Cells (VSTs), is generally safe for treating adenovirus infections in humans, especially in those with weakened immune systems. Studies have shown that this therapy can effectively manage viral infections without significant acute toxicity or increased risk of graft-versus-host disease (a condition where donor cells attack the recipient's body).15678
How is Donor T Cell Therapy different from other treatments for adenovirus infections?
Donor T Cell Therapy is unique because it uses virus-specific T cells from a donor to help the patient's immune system fight adenovirus infections, especially in those with weakened immune systems after stem cell transplants. Unlike traditional antiviral drugs, which can have limited effectiveness and significant side effects, this therapy directly boosts the body's ability to target and eliminate the virus.12357
Research Team
David Marin
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for immunocompromised patients with blood cancers and asymptomatic adenovirus viremia, or those showing probable or definitive signs of the disease. Participants must consent, not be pregnant, agree to use contraception if applicable, and cannot have certain uncontrolled infections or recent treatments that suppress the immune system.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive allogeneic adenovirus-specific cytotoxic T lymphocytes intravenously over 30 minutes. Additional infusions may be given at the discretion of the investigator.
Follow-up
Participants are monitored for safety, efficacy, and persistence of the administered cells after treatment
Treatment Details
Interventions
- Donor T Cell Therapy (T-cell Therapy)
Donor T Cell Therapy is already approved in United States, European Union for the following indications:
- Adenovirus-related disease in immunocompromised patients
- Refractory adenovirus infections post allogeneic hematopoietic stem cell transplantation
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator